JP2020514344A - 重水素化イミダゾ［４，５−ｃ］キノリン−２−オン化合物及び癌の治療におけるその使用 - Google Patents

重水素化イミダゾ［４，５−ｃ］キノリン−２−オン化合物及び癌の治療におけるその使用 Download PDF

Info

Publication number
JP2020514344A
JP2020514344A JP2019549446A JP2019549446A JP2020514344A JP 2020514344 A JP2020514344 A JP 2020514344A JP 2019549446 A JP2019549446 A JP 2019549446A JP 2019549446 A JP2019549446 A JP 2019549446A JP 2020514344 A JP2020514344 A JP 2020514344A
Authority
JP
Japan
Prior art keywords
cancer
compound
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019549446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514344A5 (enExample
Inventor
カート・ゴードン・パイク
ベルナール・クリストフ・バルラーム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2020514344A publication Critical patent/JP2020514344A/ja
Publication of JP2020514344A5 publication Critical patent/JP2020514344A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019549446A 2017-03-16 2018-03-15 重水素化イミダゾ［４，５−ｃ］キノリン−２−オン化合物及び癌の治療におけるその使用 Ceased JP2020514344A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472080P 2017-03-16 2017-03-16
US62/472,080 2017-03-16
PCT/EP2018/056516 WO2018167203A1 (en) 2017-03-16 2018-03-15 Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (2)

Publication Number Publication Date
JP2020514344A true JP2020514344A (ja) 2020-05-21
JP2020514344A5 JP2020514344A5 (enExample) 2021-04-01

Family

ID=61801891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019549446A Ceased JP2020514344A (ja) 2017-03-16 2018-03-15 重水素化イミダゾ［４，５−ｃ］キノリン−２−オン化合物及び癌の治療におけるその使用

Country Status (25)

Country Link
US (2) US20200087300A1 (enExample)
EP (1) EP3596076A1 (enExample)
JP (1) JP2020514344A (enExample)
KR (1) KR20190129923A (enExample)
CN (1) CN110431139B (enExample)
AU (1) AU2018234985B2 (enExample)
BR (1) BR112019018723A2 (enExample)
CA (1) CA3055258A1 (enExample)
CL (1) CL2019002527A1 (enExample)
CO (1) CO2019010029A2 (enExample)
CR (1) CR20190429A (enExample)
DO (1) DOP2019000228A (enExample)
EA (1) EA038233B1 (enExample)
EC (1) ECSP19066134A (enExample)
IL (1) IL269272A (enExample)
JO (1) JOP20190209A1 (enExample)
MA (1) MA49884A (enExample)
MX (1) MX2019010898A (enExample)
NI (1) NI201900094A (enExample)
PE (1) PE20191486A1 (enExample)
PH (1) PH12019502086A1 (enExample)
SG (1) SG11201908065YA (enExample)
TW (1) TW201843151A (enExample)
UA (1) UA124554C2 (enExample)
WO (1) WO2018167203A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV15575A (lv) 2019-12-20 2021-06-20 Latvijas Organiskās Sintēzes Institūts Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana
TW202216209A (zh) 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及atm抑制劑之組合
WO2022060377A1 (en) * 2020-09-21 2022-03-24 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022128833A1 (en) 2020-12-15 2022-06-23 Merck Patent Gmbh Solid transition metal-ligand complexes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
JP2012528828A (ja) * 2009-06-04 2012-11-15 ノバルティス アーゲー １Ｈ−イミダゾ［４，５−ｃ］キノリノン誘導体
WO2016155884A1 (de) * 2015-04-02 2016-10-06 Merck Patent Gmbh Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren
WO2017046216A1 (en) * 2015-09-17 2017-03-23 Astrazeneca Ab 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
NO2714752T3 (enExample) * 2014-05-08 2018-04-21

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
JP2012528828A (ja) * 2009-06-04 2012-11-15 ノバルティス アーゲー １Ｈ−イミダゾ［４，５−ｃ］キノリノン誘導体
WO2016155884A1 (de) * 2015-04-02 2016-10-06 Merck Patent Gmbh Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren
WO2017046216A1 (en) * 2015-09-17 2017-03-23 Astrazeneca Ab 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer

Also Published As

Publication number Publication date
UA124554C2 (uk) 2021-10-05
EA038233B1 (ru) 2021-07-28
BR112019018723A2 (pt) 2020-04-07
NI201900094A (es) 2020-03-18
AU2018234985B2 (en) 2020-04-02
IL269272A (en) 2019-11-28
PE20191486A1 (es) 2019-10-18
CR20190429A (es) 2019-11-12
CN110431139A (zh) 2019-11-08
KR20190129923A (ko) 2019-11-20
CN110431139B (zh) 2022-07-05
AU2018234985A1 (en) 2019-10-24
SG11201908065YA (en) 2019-09-27
ECSP19066134A (es) 2019-09-30
TW201843151A (zh) 2018-12-16
CL2019002527A1 (es) 2019-11-22
MA49884A (fr) 2020-06-24
CA3055258A1 (en) 2018-09-20
EP3596076A1 (en) 2020-01-22
US20210347775A1 (en) 2021-11-11
PH12019502086A1 (en) 2020-03-09
EA201992090A1 (ru) 2020-03-06
US20200087300A1 (en) 2020-03-19
JOP20190209A1 (ar) 2019-09-12
DOP2019000228A (es) 2019-09-30
WO2018167203A1 (en) 2018-09-20
MX2019010898A (es) 2019-11-07
CO2019010029A2 (es) 2019-09-30

Similar Documents

Publication Publication Date Title
US11613539B2 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US10189834B2 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US20180318287A1 (en) Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer
US20210347775A1 (en) Deuterated Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer
TW201805284A (zh) 咪唑并［4，5－c］喹啉－2酮化合物及其治療癌症之用途
WO2019057757A1 (en) 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
TW201808939A (zh) <img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>啉-4-胺化合物及其在治療癌症中之用途
HK40016607A (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
HK1257413B (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
HK1232528B (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
HK1232528A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220125

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220308

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20220726